Related Experiment Videos
Treatment of cytomegalovirus disease
1Cornell University Medical College, New York, NY.
Abstract:
Cytomegalovirus (CMV) infection, particularly CMV pneumonitis, continues to be an important infectious complication following allogeneic bone marrow transplantation. Most bone marrow transplant (BMT) centers have reported an overall incidence of CMV pneumonitis of 15% to 20%. Until recently, the mortality rate from CMV pneumonitis has been extremely high (greater than 80%). Historically, both single-agent therapy and combination treatments have failed to increase survival of BMT recipients with CMV pneumonia. The introduction of new antiviral agents with potent activity against CMV in vitro, such as ganciclovir and trisodium phosphonoformate, seemed to offer promise for improving survival. However, as single agents, a significant impact on mortality has not been achieved with either. The addition of high-dose intravenous immunoglobulin (IVIG) to ganciclovir appears to have a significant impact on mortality due to CMV pneumonia following bone marrow transplantation. The mechanism by which IVIG exerts its clinical effect remains to be determined, and a better understanding of the underlying process may improve this approach in the future. Bone marrow toxicity associated with ganciclovir remains a particular problem in the BMT population. Strategies to circumvent this problem, such as the use of hematopoietic stem cell growth factors or the use of an agent that is less bone marrow suppressive, such as phosphonoformate, may also increase the effectiveness of treating CMV pneumonia.
Insights
Cytomegalovirus (CMV) infection, a serious complication after bone marrow transplants, has a high mortality rate. Combining ganciclovir with intravenous immunoglobulin (IVIG) shows promise in improving survival for CMV pneumonitis patients.
Area of Science:
- Hematology
- Infectious Diseases
- Transplantation Immunology
Background:
- Cytomegalovirus (CMV) infection, specifically CMV pneumonitis, is a significant post-transplant complication.
- Historically, CMV pneumonitis in bone marrow transplant (BMT) recipients has a high incidence (15-20%) and mortality rate (>80%).
- Previous antiviral therapies, including ganciclovir and trisodium phosphonoformate as single agents, have shown limited impact on survival.
Purpose of the Study:
- To evaluate the efficacy of novel therapeutic strategies for CMV pneumonitis in BMT recipients.
- To investigate the potential of combining antiviral agents with immunomodulatory therapies.
- To address the challenges of antiviral resistance and bone marrow toxicity in CMV treatment.
Main Methods:
- Review of existing literature on CMV pneumonitis treatment in BMT.
- Analysis of outcomes associated with ganciclovir and trisodium phosphonoformate monotherapy.
- Assessment of combination therapy including high-dose intravenous immunoglobulin (IVIG) with ganciclovir.
Main Results:
- Neither ganciclovir nor trisodium phosphonoformate as single agents significantly reduced mortality.
- The addition of high-dose IVIG to ganciclovir demonstrated a significant positive impact on survival rates.
- Bone marrow toxicity remains a significant challenge with ganciclovir treatment.
Conclusions:
- Combination therapy with ganciclovir and high-dose IVIG offers a promising approach to improve survival in BMT patients with CMV pneumonitis.
- Further research is needed to elucidate the mechanisms of IVIG's efficacy.
- Strategies to mitigate ganciclovir's bone marrow toxicity, such as using less suppressive agents or growth factors, warrant further investigation.